科研製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2021/12/24 | 4,230 | 4,240 | 4,200 | 4,215 | ±0 | ±0% | 33,600 |
| 2021/12/23 | 4,265 | 4,275 | 4,205 | 4,215 | -15 | -0.4% | 38,600 |
| 2021/12/22 | 4,240 | 4,265 | 4,215 | 4,230 | -10 | -0.2% | 50,800 |
| 2021/12/21 | 4,230 | 4,280 | 4,230 | 4,240 | +15 | +0.4% | 60,300 |
| 2021/12/20 | 4,195 | 4,230 | 4,175 | 4,225 | +5 | +0.1% | 74,900 |
| 2021/12/17 | 4,215 | 4,245 | 4,195 | 4,220 | -10 | -0.2% | 107,700 |
| 2021/12/16 | 4,225 | 4,235 | 4,195 | 4,230 | +60 | +1.4% | 53,000 |
| 2021/12/15 | 4,145 | 4,200 | 4,145 | 4,170 | ±0 | ±0% | 42,800 |
| 2021/12/14 | 4,130 | 4,190 | 4,130 | 4,170 | +55 | +1.3% | 66,100 |
| 2021/12/13 | 4,175 | 4,175 | 4,110 | 4,115 | -20 | -0.5% | 51,100 |
| 2021/12/10 | 4,140 | 4,150 | 4,115 | 4,135 | -50 | -1.2% | 75,200 |
| 2021/12/09 | 4,260 | 4,260 | 4,165 | 4,185 | -40 | -0.9% | 54,300 |
| 2021/12/08 | 4,235 | 4,250 | 4,205 | 4,225 | -15 | -0.4% | 86,000 |
| 2021/12/07 | 4,195 | 4,240 | 4,150 | 4,240 | +85 | +2% | 93,300 |
| 2021/12/06 | 4,210 | 4,240 | 4,150 | 4,155 | -15 | -0.4% | 58,200 |
| 2021/12/03 | 4,085 | 4,175 | 4,085 | 4,170 | +85 | +2.1% | 76,200 |
| 2021/12/02 | 4,025 | 4,125 | 4,010 | 4,085 | +40 | +1% | 87,200 |
| 2021/12/01 | 4,030 | 4,065 | 4,010 | 4,045 | ±0 | ±0% | 92,500 |
| 2021/11/30 | 4,070 | 4,125 | 4,045 | 4,045 | -35 | -0.9% | 122,200 |
| 2021/11/29 | 4,095 | 4,120 | 4,080 | 4,080 | -60 | -1.4% | 87,300 |
| 2021/11/26 | 4,170 | 4,170 | 4,100 | 4,140 | -50 | -1.2% | 59,100 |
| 2021/11/25 | 4,190 | 4,205 | 4,175 | 4,190 | -5 | -0.1% | 33,700 |
| 2021/11/24 | 4,260 | 4,265 | 4,190 | 4,195 | -65 | -1.5% | 61,600 |
| 2021/11/22 | 4,225 | 4,270 | 4,225 | 4,260 | +5 | +0.1% | 56,900 |
| 2021/11/19 | 4,225 | 4,280 | 4,225 | 4,255 | +20 | +0.5% | 72,900 |
| 2021/11/18 | 4,250 | 4,270 | 4,230 | 4,235 | -20 | -0.5% | 72,700 |
| 2021/11/17 | 4,250 | 4,270 | 4,235 | 4,255 | -5 | -0.1% | 62,500 |
| 2021/11/16 | 4,265 | 4,295 | 4,255 | 4,260 | -40 | -0.9% | 70,300 |
| 2021/11/15 | 4,250 | 4,300 | 4,235 | 4,300 | +5 | +0.1% | 67,300 |
| 2021/11/12 | 4,265 | 4,315 | 4,265 | 4,295 | +25 | +0.6% | 52,800 |
| 2021/11/11 | 4,270 | 4,295 | 4,255 | 4,270 | -25 | -0.6% | 48,400 |
| 2021/11/10 | 4,325 | 4,330 | 4,280 | 4,295 | +40 | +0.9% | 63,100 |
| 2021/11/09 | 4,240 | 4,275 | 4,220 | 4,255 | +55 | +1.3% | 93,700 |
| 2021/11/08 | 4,285 | 4,295 | 4,195 | 4,200 | -155 | -3.6% | 105,900 |
| 2021/11/05 | 4,350 | 4,370 | 4,285 | 4,355 | -135 | -3% | 118,800 |
| 2021/11/04 | 4,575 | 4,580 | 4,360 | 4,490 | -15 | -0.3% | 179,800 |
| 2021/11/02 | 4,500 | 4,540 | 4,485 | 4,505 | -65 | -1.4% | 69,200 |
| 2021/11/01 | 4,590 | 4,590 | 4,530 | 4,570 | +80 | +1.8% | 78,500 |
| 2021/10/29 | 4,485 | 4,500 | 4,430 | 4,490 | -10 | -0.2% | 83,700 |
| 2021/10/28 | 4,515 | 4,520 | 4,485 | 4,500 | -20 | -0.4% | 344,800 |
| 2021/10/27 | 4,520 | 4,545 | 4,500 | 4,520 | +30 | +0.7% | 110,100 |
| 2021/10/26 | 4,460 | 4,520 | 4,455 | 4,490 | +10 | +0.2% | 79,400 |
| 2021/10/25 | 4,480 | 4,540 | 4,475 | 4,480 | ±0 | ±0% | 79,100 |
| 2021/10/22 | 4,465 | 4,520 | 4,460 | 4,480 | -25 | -0.6% | 101,700 |
| 2021/10/21 | 4,495 | 4,580 | 4,475 | 4,505 | +30 | +0.7% | 163,000 |
| 2021/10/20 | 4,485 | 4,500 | 4,445 | 4,475 | -5 | -0.1% | 73,000 |
| 2021/10/19 | 4,440 | 4,480 | 4,440 | 4,480 | +55 | +1.2% | 59,400 |
| 2021/10/18 | 4,490 | 4,495 | 4,420 | 4,425 | -115 | -2.5% | 76,300 |
| 2021/10/15 | 4,430 | 4,545 | 4,430 | 4,540 | +85 | +1.9% | 72,600 |
| 2021/10/14 | 4,425 | 4,490 | 4,415 | 4,455 | +35 | +0.8% | 103,700 |
851～
900
件表示中 / 3723件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 科研薬 | 386,000円 | -6.4% | -71.8% | 4.92% | 43.11倍 | 0.96倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
| ジーエヌアイ | 378,000円 | +21.7% | +999.9% | 0.00% | 15.84倍 | 5.24倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
| 鳥居薬 | 634,000円 | +7.1% | -35.0% | 0.00% | 52.43倍 | 1.47倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
| 東和薬品 | 299,900円 | +7.9% | -3.3% | 2.67% | 8.34倍 | 0.86倍 |
|
後発医薬品メーカーで国内２強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
| ゼリア新薬 | 203,900円 | +3.1% | -6.5% | 2.35% | 9.46倍 | 1.00倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
